

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

INSIDE INFORMATION – 2022 PRELIMINARY RESULTS

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) as well as the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Please also refer to the overseas regulatory announcement of the Company dated 27 February 2023.

The principal consolidated financial data of the Company for the year ended 31 December 2022 (the “**Reporting Period**”) as set out in this announcement and prepared in accordance with the China Accounting Standards for Business Enterprises is only preliminary estimated data, and has not been audited. This preliminary results is prepared pursuant to the relevant regulations of the Shanghai Stock Exchange and the People's Republic of China. The audited financial data of the Company for the Reporting Period will be disclosed in the 2022 annual report of the Company (prepared in accordance with PRC GAAP) to be published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>), and the 2022 annual results announcement and the 2022 annual report of the Company (prepared in accordance with International Financial Reporting Standards) to be published on the websites of the Company (www.junshipharma.com) and The Stock Exchange of Hong Kong Limited (<http://www.hkexnews.hk>). Shareholders and investors are advised to exercise caution when dealing in the shares of the Company.

I. MAJOR FINANCIAL DATA AND INDICATORS FOR 2022

Unit: RMB'0,000

Item	The Reporting Period	Corresponding period of last year	Change (%)
Total operating income	145,342.99	402,484.09	(63.89)
Operating loss	(267,439.60)	(55,827.45)	N/A
Total loss	(268,566.58)	(59,500.05)	N/A
Net loss attributable to owners of the parent company	(239,766.74)	(72,090.97)	N/A
Net loss attributable to owners of the parent company after deducting non-recurring gains and losses	(245,981.51)	(88,404.89)	N/A
Basic loss per share (RMB)	(2.61)	(0.81)	N/A
			decrease by 21.94 percentage points
Weighted average returns on net assets	(32.80%)	(10.86%)	percentage points
	At the end of the Reporting Period	At the beginning of the Reporting Period	Change (%)
Total assets	1,255,137.95	1,103,491.11	13.74
Equity attributable to owners of the parent company	947,400.86	794,509.54	19.24
Share capital (share)	98,287.16	91,075.67	7.92
Net assets per share attributable to owners of the parent company (RMB)	9.64	8.72	10.55

Notes: 1. The data as at the beginning of the Reporting Period is the same as the data disclosed statutorily as at the end of last year.

2. The financial data and indicators above are extracted from the data of the consolidated financial statements and are unaudited. The final results are subject to the 2022 annual report of the Company.

II. EXPLANATION ON THE OPERATING RESULTS AND FINANCIAL POSITION

(I) Operating conditions, financial position and major factors affecting the operating results during the Reporting Period:

During the Reporting Period, the Company recorded less operating income, the main reason of which was that significant licensing income and royalty income generated from etesevimab (JS016/LY-CoV016), a neutralizing antibody for COVID-19, in the overseas markets where the Company cooperated with Eli Lilly and Company were recorded in the previous reporting period, whereas the corresponding licensing income decreased during the Reporting Period since all milestones of the above cooperation had been achieved and such revenue was recognized in 2021.

In 2022, one of the Company's core products toripalimab injection (trade name: TUOYI®) achieved a year-on-year significant increase in sales revenue compared with 2021. With the increase in commercialization capability and approval of two additional large indications for toripalimab during the Reporting Period, the sales of the Company in the domestic market are gradually entering into a positive cycle.

The Company continuously enriched its product pipeline, explored the combination therapy of drugs, invested corresponding research and development (“R&D”) expenditures according to the R&D process, accelerated the development of existing clinical projects and reserved R&D projects, as well as accelerated the development of a number of product pipelines with first-in-class or differentiated development value during the Reporting Period. During the Reporting Period, two additional indications for toripalimab have been approved for marketing by the National Medical Products Administration (the “NMPA”); eight indications for adalimumab (trade name: JUNMAIKANG®) have been approved for marketing by the NMPA; nine pipeline assets have been approved for clinical trials by the NMPA and three pipeline assets have been approved for clinical trials by the U.S. Food and Drug Administration.

(II) Main reasons for the changes in the major indicators

1. During the Reporting Period, the Company's operating income decreased by 63.89% as compared with the same period of last year, the main reason of which was that the Company recorded significant licensing income and royalty income generated from etesevimab (JS016/LY-CoV016), a neutralizing antibody for COVID-19, in the overseas markets where the Company cooperated with Eli Lilly and Company in the previous reporting period, but since all milestones of the above cooperation had been achieved and such revenue was recognized in 2021, therefore the corresponding licensing income decreased during the Reporting Period.
2. During the Reporting Period, the operating loss, total loss, net loss attributable to owners of the parent company, net loss attributable to owners of the parent company after deducting non-recurring gains and losses, basic loss per share increased while the weighted average returns on net assets decreased as compared with the same period of last year, which were mainly due to the decrease in corresponding licensing income during the Reporting Period.
3. As at the end of the Reporting Period, total assets, equity attributable to owners of the parent company, share capital and net assets per share attributable to owners of the parent company increased by 13.74%, 19.24%, 7.92% and 10.55% as compared with the same period of last year, respectively, which were mainly due to the receipt of raised funds from the issuance of A shares to target subscribers by the Company during the Reporting Period.

III. RISK WARNING

The Company is not aware of any material uncertainties that will affect the accuracy of the content of this preliminary results announcement.

The major financial data for 2022 contained in this announcement is only preliminary estimated data, and has not been audited by certified public accountant. Please refer to the 2022 annual report of the Company for specific audited data. Investors are reminded of the investment risks.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 27 February 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong and Dr. Zou Jianjun as executive Directors; Dr. Wu Hai and Mr. Tang Yi as non-executive Directors; and Dr. Chen Lieping, Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun and Dr. Feng Xiaoyuan as independent non-executive Directors.

* For identification purpose only